Antibodies for the treatment of synucleinopathy
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
1. A monoclonal antibody which specifically binds to human alpha-synuclein and comprises:
(a) a Heavy Chain CDR1 comprising the amino acid sequence of SEQ ID NO:1;
(b) a Heavy Chain CDR2 comprising the amino acid sequence of SEQ ID NO:2;
(c) a Heavy Chain CDR3 comprising the amino acid sequence of SEQ ID NO:3;
(d) a Light Chain CDR1 comprising the amino acid sequence of SEQ ID NO:4;
(e) a Light Chain CDR2 comprising the amino acid sequence of SEQ ID NO:5; and
(f) a Light Chain CDR3 comprising the amino acid sequence of SEQ ID NO:6.
2. The antibody of claim 1 , which is a single chain Fv, a disulphide-bonded Fv, an Fab fragment, a Fab′ fragment, or a F(ab) 2 fragment.
3. The antibody of claim 1 , wherein the antibody is a human antibody.
4. The antibody of claim 1 , wherein the antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8.
5. A pharmaceutical composition comprising the antibody of claim 1 , and a pharmaceutical acceptable carrier.
6. The antibody of claim 1 , which further comprises a detectable label.
7. The antibody of claim 6 , wherein the detectable label is a fluorescent label, a chemiluminescent label, a paramagnetic label, a radioisotopic label or an enzyme label.
8. A pharmaceutical composition comprising the antibody of claim 6 , and a pharmaceutically acceptable carrier.
9. The antibody of claim 1 , wherein the antibody binds an epitope within amino acid residues 112-117 (SEQ ID NO:9) of human alpha-synuclein (SEQ ID NO:10).